Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institution

Breast J. 2019 Nov;25(6):1225-1229. doi: 10.1111/tbj.13437. Epub 2019 Jul 16.

Abstract

Overall survival (OS), disease-free survival (DFS), and distant recurrence-free interval (DRFI) were evaluated from 169 patients diagnosed with early triple negative breast cancer. Overall, 5 and 10 years OS, DFS, and DRFI were 77% and 65%; 60% and 46%; and 74% and 73%, respectively. Forty-seven patients did not receive chemotherapy. A separate analysis was performed excluding those patients. In this subgroup, 5- and 10-year OS, DFS, and DRFI were 86% and 77%; 68% and 54%, 77% both at 5 and 10 years. Prognosis is better than previously described; adjuvant chemotherapy should be offered to fit elderly patients if clinically warranted.

Keywords: breast cancer; elderly; outcome; prognosis; triple negative.

MeSH terms

  • Age Factors
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Chemotherapy, Adjuvant / methods
  • Disease-Free Survival
  • Female
  • Humans
  • Italy / epidemiology
  • Middle Aged
  • Outcome and Process Assessment, Health Care
  • Patient Care Management* / methods
  • Patient Care Management* / statistics & numerical data
  • Patient Care Management* / trends
  • Prognosis
  • Retrospective Studies
  • Triple Negative Breast Neoplasms / epidemiology
  • Triple Negative Breast Neoplasms / pathology
  • Triple Negative Breast Neoplasms / therapy*